Global Continuous Blood Glucose Monitoring Market Overview

The Global Continuous Blood Glucose Monitoring Market Is Expected to Grow at A Significant Growth Rate, And the Analysis Period Is 2022-2028, Considering the Base Year As 2021.

Continuous glucose monitoring tracks blood glucose levels, also known as blood sugar, automatically 24 hours a day, seven days a week. You can view your glucose level at any time. You can also review your glucose levels over the course of a few hours or days to identify trends. Real-time glucose monitoring enables you to make more informed choices throughout the day regarding how to balance your diet, physical activity, and medications. A CGM operates through a tiny sensor inserted subcutaneously, typically on the abdomen or arm. The glucose concentration in the fluid between your cells is measured by the sensor. The glucose sensor performs tests every few minutes. The information is transmitted wirelessly to the monitor by a transmitter.

CGM is one of the most recent technological advances in diabetes management (continuous glucose monitoring). In the case of CGM, a biosensor, a type of glucose monitoring device, is inserted transcutaneous or subcutaneously into the subject's body. The embedded sensor detects glucose levels in the blood or interstitial fluid and transmits the data to a monitor/receiver via a type of transmitter. These systems are crucial for managing diabetes due to their numerous advantages over conventional glucose monitoring devices. Unlike conventional glucose monitors, these devices provide routine glucose monitoring, which is crucial for preventing diabetes-related complications.

Market Dynamics And Factors For Continuous Blood Glucose Monitoring Market

Drivers:

• Increasing incidence of diabetes

Restraints:

• Variability in Medicare Reimbursement

Opportunity:

• To Developed More Technologically Advanced Product

Challenges:

• High Cost of the Devices

Regional Analysis In Continuous Blood Glucose Monitoring Market

North America dominated the global CGM device market with a market share of over 39 percent. Due to the region's well-established healthcare industry, growth is anticipated during the forecast period. The growing awareness of advanced technologies for diabetes control, the rising prevalence of obesity, and favorable reimbursement policies all contribute to the expansion of this region. In the Asia-Pacific region, the number of diabetic patients is increasing. The International Diabetes Federation reports that India and China have the most diabetic patients in the world. Due to the rise of obesity and socioeconomic inequality, Type 1 and Type 2 diabetes have become increasingly prevalent.

The Asia-Pacific region is experiencing a greater increase in diabetic patients than other global regions. IDF reports that India and China have the most diabetic patients in the world (International Diabetes Federation). Due to rising socioeconomic inequality and an increase in obesity cases, Type I and Type II diabetes have become extremely common.

Covid-19 Impact Analysis On Continuous Blood Glucose Monitoring Market

This virus causes a life-threatening infection known as COVID-19. Due to COVID, the global market for Continuous Glucose Monitoring (CGM) devices has expanded. According to the Centers for Disease Control and Prevention, diabetes patients in the United States have a threefold increased risk of hospitalization and a twofold increased risk of high severity. The Food and Drug Administration (FDA) of the United States issued a policy in March 2020 to expand the availability of noninvasive glucose monitoring devices, primarily in hospitals. Since governments encouraged hospitals to monitor diabetic patients without contacting them, the utilization of CGM devices in hospitals has increased over time. During the COVID-19 pandemic, the utilization of CGM devices in ICUs has increased globally.

COVID-19 is anticipated to contribute to the expansion of the market for continuous glucose monitoring devices, as the virus has been found to be harmful to diabetics. According to the American Diabetes Association, there is currently insufficient evidence to determine if people with diabetes are more likely to contract COVID-19, but they can experience worse outcomes, such as higher rates of serious complications.

Top Key Players Covered In Continuous Blood Glucose Monitoring Market

• Abbott Laboratories(U.S)
• Dexcom Inc (U.S)
• LifeScan I.P. Holdings LLC (U.S)
• Medtronic plc (Ireland)
• Terumo Corporation (Japan)
• Johnson & Johnson (U.S)
• GlySens Incorporated (U.S)
• A Menarini Diagnostics (Italy)
• Nemaura Medical Inc (U.S)
• Echo Therapeutics Inc (U.S)
• Senseonics Holdings Inc (U.S)
• Hoffmann-La Roche Ltd (Switzerland)
• Ypsomed AG (Switzerland), and other major players

Key Industry Development In The Continuous Blood Glucose Monitoring Market

In September 2022, Cardiff University and GlucoRx have announced the release of the world's first non-invasive continuous glucose monitor, ushering in a new era of needle-free monitoring for diabetics.

In August 2022, Dexcom and NHS England have announced the availability of Dexcom ONE rt-CGM systems on prescription through the drug tariffs of Wales, NHS England, Scotland, and Northern Ireland for insulin-using patients with Type 1 or Type 2 diabetes.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Product
 3.2 By Application

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Continuous Blood Glucose Monitoring Market by Product
 5.1 Continuous Blood Glucose Monitoring Market Overview Snapshot and Growth Engine
 5.2 Continuous Blood Glucose Monitoring Market Overview
 5.3 CBM (Transmitters
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 CBM (Transmitters: Geographic Segmentation
 5.4 Sensors
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Sensors: Geographic Segmentation
 5.5 receiver)
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 receiver): Geographic Segmentation
 5.6 SMBG Systems (Blood Glucose Meters
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 SMBG Systems (Blood Glucose Meters: Geographic Segmentation
 5.7 Testing Strips
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size (2016-2028F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Testing Strips: Geographic Segmentation
 5.8 Lancets)
  5.8.1 Introduction and Market Overview
  5.8.2 Historic and Forecasted Market Size (2016-2028F)
  5.8.3 Key Market Trends, Growth Factors and Opportunities
  5.8.4 Lancets): Geographic Segmentation

Chapter 6: Continuous Blood Glucose Monitoring Market by Application
 6.1 Continuous Blood Glucose Monitoring Market Overview Snapshot and Growth Engine
 6.2 Continuous Blood Glucose Monitoring Market Overview
 6.3 Type 1 Diabetes
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Type 1 Diabetes: Geographic Segmentation
 6.4 Type 2 Diabetes
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Type 2 Diabetes: Geographic Segmentation
 6.5 Gestational Diabetes
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Gestational Diabetes : Geographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Positioning
  7.1.2 Continuous Blood Glucose Monitoring Sales and Market Share By Players
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Continuous Blood Glucose Monitoring Industry Concentration Ratio (CR5 and HHI)
  7.1.6 Top 5 Continuous Blood Glucose Monitoring Players Market Share
  7.1.7 Mergers and Acquisitions
  7.1.8 Business Strategies By Top Players
 7.2 ABBOTT LABORATORIES (U.S)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Operating Business Segments
  7.2.5 Product Portfolio
  7.2.6 Business Performance
  7.2.7 Key Strategic Moves and Recent Developments
  7.2.8 SWOT Analysis
 7.3 DEXCOM INC (U.S)
 7.4 LIFESCAN I.P. HOLDINGS LLC (U.S)
 7.5 MEDTRONIC PLC (IRELAND)
 7.6 TERUMO CORPORATION (JAPAN)
 7.7 JOHNSON & JOHNSON (U.S)
 7.8 GLYSENS INCORPORATED (U.S)
 7.9 A MENARINI DIAGNOSTICS (ITALY)
 7.10 NEMAURA MEDICAL INC (U.S)
 7.11 ECHO THERAPEUTICS INC (U.S)
 7.12 SENSEONICS HOLDINGS INC (U.S)
 7.13 HOFFMANN-LA ROCHE LTD (SWITZERLAND)
 7.14 YPSOMED AG (SWITZERLAND)
 7.15 OTHER MAJOR PLAYERS

Chapter 8: Global Continuous Blood Glucose Monitoring Market Analysis, Insights and Forecast, 2016-2028
 8.1 Market Overview
 8.2 Historic and Forecasted Market Size By Product
  8.2.1 CBM (Transmitters
  8.2.2 Sensors
  8.2.3 receiver)
  8.2.4 SMBG Systems (Blood Glucose Meters
  8.2.5 Testing Strips
  8.2.6 Lancets)
 8.3 Historic and Forecasted Market Size By Application
  8.3.1 Type 1 Diabetes
  8.3.2 Type 2 Diabetes
  8.3.3 Gestational Diabetes

Chapter 9: North America Continuous Blood Glucose Monitoring Market Analysis, Insights and Forecast, 2016-2028
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By Product
  9.4.1 CBM (Transmitters
  9.4.2 Sensors
  9.4.3 receiver)
  9.4.4 SMBG Systems (Blood Glucose Meters
  9.4.5 Testing Strips
  9.4.6 Lancets)
 9.5 Historic and Forecasted Market Size By Application
  9.5.1 Type 1 Diabetes
  9.5.2 Type 2 Diabetes
  9.5.3 Gestational Diabetes
 9.6 Historic and Forecast Market Size by Country
  9.6.1 U.S.
  9.6.2 Canada
  9.6.3 Mexico

Chapter 10: Europe Continuous Blood Glucose Monitoring Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Product
  10.4.1 CBM (Transmitters
  10.4.2 Sensors
  10.4.3 receiver)
  10.4.4 SMBG Systems (Blood Glucose Meters
  10.4.5 Testing Strips
  10.4.6 Lancets)
 10.5 Historic and Forecasted Market Size By Application
  10.5.1 Type 1 Diabetes
  10.5.2 Type 2 Diabetes
  10.5.3 Gestational Diabetes
 10.6 Historic and Forecast Market Size by Country
  10.6.1 Germany
  10.6.2 U.K.
  10.6.3 France
  10.6.4 Italy
  10.6.5 Russia
  10.6.6 Spain
  10.6.7 Rest of Europe

Chapter 11: Asia-Pacific Continuous Blood Glucose Monitoring Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Product
  11.4.1 CBM (Transmitters
  11.4.2 Sensors
  11.4.3 receiver)
  11.4.4 SMBG Systems (Blood Glucose Meters
  11.4.5 Testing Strips
  11.4.6 Lancets)
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Type 1 Diabetes
  11.5.2 Type 2 Diabetes
  11.5.3 Gestational Diabetes
 11.6 Historic and Forecast Market Size by Country
  11.6.1 China
  11.6.2 India
  11.6.3 Japan
  11.6.4 Singapore
  11.6.5 Australia
  11.6.6 New Zealand
  11.6.7 Rest of APAC

Chapter 12: Middle East & Africa Continuous Blood Glucose Monitoring Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Product
  12.4.1 CBM (Transmitters
  12.4.2 Sensors
  12.4.3 receiver)
  12.4.4 SMBG Systems (Blood Glucose Meters
  12.4.5 Testing Strips
  12.4.6 Lancets)
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Type 1 Diabetes
  12.5.2 Type 2 Diabetes
  12.5.3 Gestational Diabetes
 12.6 Historic and Forecast Market Size by Country
  12.6.1 Turkey
  12.6.2 Saudi Arabia
  12.6.3 Iran
  12.6.4 UAE
  12.6.5 Africa
  12.6.6 Rest of MEA

Chapter 13: South America Continuous Blood Glucose Monitoring Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Product
  13.4.1 CBM (Transmitters
  13.4.2 Sensors
  13.4.3 receiver)
  13.4.4 SMBG Systems (Blood Glucose Meters
  13.4.5 Testing Strips
  13.4.6 Lancets)
 13.5 Historic and Forecasted Market Size By Application
  13.5.1 Type 1 Diabetes
  13.5.2 Type 2 Diabetes
  13.5.3 Gestational Diabetes
 13.6 Historic and Forecast Market Size by Country
  13.6.1 Brazil
  13.6.2 Argentina
  13.6.3 Rest of SA

Chapter 14 Investment Analysis

Chapter 15 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET COMPETITIVE RIVALRY
TABLE 005. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET THREAT OF NEW ENTRANTS
TABLE 006. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET THREAT OF SUBSTITUTES
TABLE 007. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET BY PRODUCT
TABLE 008. CBM (TRANSMITTERS MARKET OVERVIEW (2016-2028)
TABLE 009. SENSORS MARKET OVERVIEW (2016-2028)
TABLE 010. RECEIVER) MARKET OVERVIEW (2016-2028)
TABLE 011. SMBG SYSTEMS (BLOOD GLUCOSE METERS MARKET OVERVIEW (2016-2028)
TABLE 012. TESTING STRIPS MARKET OVERVIEW (2016-2028)
TABLE 013. LANCETS) MARKET OVERVIEW (2016-2028)
TABLE 014. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET BY APPLICATION
TABLE 015. TYPE 1 DIABETES MARKET OVERVIEW (2016-2028)
TABLE 016. TYPE 2 DIABETES MARKET OVERVIEW (2016-2028)
TABLE 017. GESTATIONAL DIABETES MARKET OVERVIEW (2016-2028)
TABLE 018. NORTH AMERICA CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY PRODUCT (2016-2028)
TABLE 019. NORTH AMERICA CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY APPLICATION (2016-2028)
TABLE 020. N CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY COUNTRY (2016-2028)
TABLE 021. EUROPE CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY PRODUCT (2016-2028)
TABLE 022. EUROPE CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY APPLICATION (2016-2028)
TABLE 023. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY COUNTRY (2016-2028)
TABLE 024. ASIA PACIFIC CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY PRODUCT (2016-2028)
TABLE 025. ASIA PACIFIC CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY APPLICATION (2016-2028)
TABLE 026. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY COUNTRY (2016-2028)
TABLE 027. MIDDLE EAST & AFRICA CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY PRODUCT (2016-2028)
TABLE 028. MIDDLE EAST & AFRICA CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY APPLICATION (2016-2028)
TABLE 029. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY COUNTRY (2016-2028)
TABLE 030. SOUTH AMERICA CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY PRODUCT (2016-2028)
TABLE 031. SOUTH AMERICA CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY APPLICATION (2016-2028)
TABLE 032. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET, BY COUNTRY (2016-2028)
TABLE 033. ABBOTT LABORATORIES (U.S): SNAPSHOT
TABLE 034. ABBOTT LABORATORIES (U.S): BUSINESS PERFORMANCE
TABLE 035. ABBOTT LABORATORIES (U.S): PRODUCT PORTFOLIO
TABLE 036. ABBOTT LABORATORIES (U.S): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 036. DEXCOM INC (U.S): SNAPSHOT
TABLE 037. DEXCOM INC (U.S): BUSINESS PERFORMANCE
TABLE 038. DEXCOM INC (U.S): PRODUCT PORTFOLIO
TABLE 039. DEXCOM INC (U.S): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 039. LIFESCAN I.P. HOLDINGS LLC (U.S): SNAPSHOT
TABLE 040. LIFESCAN I.P. HOLDINGS LLC (U.S): BUSINESS PERFORMANCE
TABLE 041. LIFESCAN I.P. HOLDINGS LLC (U.S): PRODUCT PORTFOLIO
TABLE 042. LIFESCAN I.P. HOLDINGS LLC (U.S): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 042. MEDTRONIC PLC (IRELAND): SNAPSHOT
TABLE 043. MEDTRONIC PLC (IRELAND): BUSINESS PERFORMANCE
TABLE 044. MEDTRONIC PLC (IRELAND): PRODUCT PORTFOLIO
TABLE 045. MEDTRONIC PLC (IRELAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 045. TERUMO CORPORATION (JAPAN): SNAPSHOT
TABLE 046. TERUMO CORPORATION (JAPAN): BUSINESS PERFORMANCE
TABLE 047. TERUMO CORPORATION (JAPAN): PRODUCT PORTFOLIO
TABLE 048. TERUMO CORPORATION (JAPAN): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. JOHNSON & JOHNSON (U.S): SNAPSHOT
TABLE 049. JOHNSON & JOHNSON (U.S): BUSINESS PERFORMANCE
TABLE 050. JOHNSON & JOHNSON (U.S): PRODUCT PORTFOLIO
TABLE 051. JOHNSON & JOHNSON (U.S): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. GLYSENS INCORPORATED (U.S): SNAPSHOT
TABLE 052. GLYSENS INCORPORATED (U.S): BUSINESS PERFORMANCE
TABLE 053. GLYSENS INCORPORATED (U.S): PRODUCT PORTFOLIO
TABLE 054. GLYSENS INCORPORATED (U.S): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. A MENARINI DIAGNOSTICS (ITALY): SNAPSHOT
TABLE 055. A MENARINI DIAGNOSTICS (ITALY): BUSINESS PERFORMANCE
TABLE 056. A MENARINI DIAGNOSTICS (ITALY): PRODUCT PORTFOLIO
TABLE 057. A MENARINI DIAGNOSTICS (ITALY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. NEMAURA MEDICAL INC (U.S): SNAPSHOT
TABLE 058. NEMAURA MEDICAL INC (U.S): BUSINESS PERFORMANCE
TABLE 059. NEMAURA MEDICAL INC (U.S): PRODUCT PORTFOLIO
TABLE 060. NEMAURA MEDICAL INC (U.S): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 060. ECHO THERAPEUTICS INC (U.S): SNAPSHOT
TABLE 061. ECHO THERAPEUTICS INC (U.S): BUSINESS PERFORMANCE
TABLE 062. ECHO THERAPEUTICS INC (U.S): PRODUCT PORTFOLIO
TABLE 063. ECHO THERAPEUTICS INC (U.S): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 063. SENSEONICS HOLDINGS INC (U.S): SNAPSHOT
TABLE 064. SENSEONICS HOLDINGS INC (U.S): BUSINESS PERFORMANCE
TABLE 065. SENSEONICS HOLDINGS INC (U.S): PRODUCT PORTFOLIO
TABLE 066. SENSEONICS HOLDINGS INC (U.S): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 066. HOFFMANN-LA ROCHE LTD (SWITZERLAND): SNAPSHOT
TABLE 067. HOFFMANN-LA ROCHE LTD (SWITZERLAND): BUSINESS PERFORMANCE
TABLE 068. HOFFMANN-LA ROCHE LTD (SWITZERLAND): PRODUCT PORTFOLIO
TABLE 069. HOFFMANN-LA ROCHE LTD (SWITZERLAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 069. YPSOMED AG (SWITZERLAND): SNAPSHOT
TABLE 070. YPSOMED AG (SWITZERLAND): BUSINESS PERFORMANCE
TABLE 071. YPSOMED AG (SWITZERLAND): PRODUCT PORTFOLIO
TABLE 072. YPSOMED AG (SWITZERLAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 072. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 073. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 074. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 075. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET OVERVIEW BY PRODUCT
FIGURE 012. CBM (TRANSMITTERS MARKET OVERVIEW (2016-2028)
FIGURE 013. SENSORS MARKET OVERVIEW (2016-2028)
FIGURE 014. RECEIVER) MARKET OVERVIEW (2016-2028)
FIGURE 015. SMBG SYSTEMS (BLOOD GLUCOSE METERS MARKET OVERVIEW (2016-2028)
FIGURE 016. TESTING STRIPS MARKET OVERVIEW (2016-2028)
FIGURE 017. LANCETS) MARKET OVERVIEW (2016-2028)
FIGURE 018. CONTINUOUS BLOOD GLUCOSE MONITORING MARKET OVERVIEW BY APPLICATION
FIGURE 019. TYPE 1 DIABETES MARKET OVERVIEW (2016-2028)
FIGURE 020. TYPE 2 DIABETES MARKET OVERVIEW (2016-2028)
FIGURE 021. GESTATIONAL DIABETES MARKET OVERVIEW (2016-2028)
FIGURE 022. NORTH AMERICA CONTINUOUS BLOOD GLUCOSE MONITORING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 023. EUROPE CONTINUOUS BLOOD GLUCOSE MONITORING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 024. ASIA PACIFIC CONTINUOUS BLOOD GLUCOSE MONITORING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. MIDDLE EAST & AFRICA CONTINUOUS BLOOD GLUCOSE MONITORING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. SOUTH AMERICA CONTINUOUS BLOOD GLUCOSE MONITORING MARKET OVERVIEW BY COUNTRY (2016-2028)